Inhibition of exportin 1 (XPO-1) with selinexor can prevent nuclear export of key cargo proteins, including pro-tumour eIF4E-mRNAs complexes to be translated in the cytoplasm (e.g., mRNAs for c-Myc, Bcl2, Bcl-XL, Bcl6, survivin, and cyclin D1) or factors implicated in PD-1/PD-L1 upregulation (e.g., NFATC1, and STAT1/3), and this has shown substantial improved survival in R/R DLBCL patients [246] and promising efficacy in mouse syngeneic tumour models in combination with immune-checkpoint blockade [247,248]. This evidence concerns the gene XPO1 and neoplasm.